.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BB04_Cladribine.Cladribine

Information

Cladribine is a purine nucleoside analogue used primarily as an antineoplastic agent for the treatment of hematological malignancies such as hairy cell leukemia and multiple sclerosis. Cladribine is approved for use in relapsing forms of multiple sclerosis and has demonstrated efficacy as an immunomodulatory and cytotoxic agent due to its selective cytotoxicity for lymphocytes.

Pharmacokinetics

Pharmacokinetic parameters in adult patients with multiple sclerosis following oral administration

References

1. Savic, RM, et al., & Karlsson, MO (2017). Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis. Clinical pharmacokinetics 56(10) 1245–1253. DOI:10.1007/s40262-017-0516-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28255849

2. Lindemalm, S, et al., & Albertioni, F (2005). Application of population pharmacokinetics to cladribine. BMC pharmacology 5 4–None. DOI:10.1186/1471-2210-5-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15757511

3. Meuth, SG, et al., & Hartung, HP (2018). [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods]. Der Nervenarzt 89(8) 895–907. DOI:10.1007/s00115-018-0498-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29523912

Revisions

• 06/2025 initial generated model